Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $8.33.

Several research firms recently weighed in on CGEN. StockNews.com began coverage on Compugen in a research report on Thursday, August 17th. They set a “hold” rating for the company. Truist Financial reaffirmed a “buy” rating and issued a $4.00 price target on shares of Compugen in a report on Wednesday, August 23rd.

Hedge Funds Weigh In On Compugen

A number of large investors have recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. increased its holdings in Compugen by 29.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 6,174 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Compugen by 23.4% in the first quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 6,299 shares during the period. XTX Topco Ltd boosted its stake in shares of Compugen by 23.7% in the first quarter. XTX Topco Ltd now owns 44,918 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 8,615 shares during the period. Jane Street Group LLC lifted its stake in Compugen by 13.8% during the second quarter. Jane Street Group LLC now owns 74,231 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 8,980 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Compugen during the first quarter worth $37,000. Institutional investors own 13.25% of the company’s stock.

Compugen Price Performance

Shares of NASDAQ CGEN opened at $1.14 on Friday. The stock has a market capitalization of $98.75 million, a price-to-earnings ratio of -2.85 and a beta of 2.68. The stock’s fifty day simple moving average is $1.13 and its 200 day simple moving average is $0.93. Compugen has a 52-week low of $0.51 and a 52-week high of $1.49.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. During the same period last year, the firm earned ($0.11) earnings per share. As a group, analysts anticipate that Compugen will post -0.34 earnings per share for the current year.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.